Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA3 | P22001 | 1/20 | 0.48 |
| ▸ | PRKCA | P17252 | 5/20 | 0.46 |
| ▸ | PRKCD | Q05655 | 5/20 | 0.46 |
| ▸ | PRKCB | P05771 | 4/20 | 0.46 |
| ▸ | PRKCH | P24723 | 4/20 | 0.46 |
| ▸ | PRKCE | Q02156 | 4/20 | 0.46 |
| ▸ | PRKCQ | Q04759 | 4/20 | 0.46 |
| ▸ | PRKD1 | Q15139 | 4/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.43 |
| ▸ | PRKCG | P05129 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.43 |
| ▸ | PRKACA | P17612 | 2/20 | 0.43 |
| ▸ | PRKACG | P22612 | 2/20 | 0.43 |
| ▸ | PRKACB | P22694 | 2/20 | 0.43 |
| ▸ | PRKCI | P41743 | 2/20 | 0.43 |
| ▸ | PRKCZ | Q05513 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4322649 | 0.89 | HTR2C (0.56) | HTR2CKDM4ECYP1A2MEN1HTR1A | |
| SCHEMBL4314864 | 0.84 | HTR2C (0.40) | PRKCAPRKCDPRKCBPRKCHPRKCE | |
| SCHEMBL4312087 | 0.81 | HTR2C (0.52) | HTR2CCYP3A4KDM4ECYP1A2CYP2C19 | |
| SCHEMBL4308712 | 0.80 | ADRB2 (0.45) | HTR2CCYP3A4HTR1ASLC6A4ACVR1 | |
| SCHEMBL4317211 | 0.79 | HTR2C (0.41) | HTR2CHTR1ASLC6A4HTR6 | |
| SCHEMBL4312038 | 0.78 | HTR2C (0.43) | HTR2C | |
| SCHEMBL4319483 | 0.77 | HTR1A (0.53) | HTR2CHTR1ASLC6A4HTR6 | |
| SCHEMBL4318698 | 0.77 | HTR2C (0.39) | HTR2CHTR1ASLC6A4HTR6 | |
| SCHEMBL4317632 | 0.77 | ADRB2 (0.46) | HTR2CROCK2ROCK1 | |
| SCHEMBL4312809 | 0.77 | CYP2C19 (0.49) | HTR2CCYP3A4CYP1A2CYP2C19HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7534794-B2 | Certain arylaliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases | BIOVITRUM AB (SE) | 2009-05-19 | — | — | US | disclosed |
| US-7071180-B2 | Certain arylaliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases | BIOVITRUM AB (SE) | 2006-07-04 | — | — | US | disclosed |
| EP-1178973-B1 | PYRAZINYL-PIPERAZINE- COMPOUNDS, THEIR USE AND PREPARATION | BIOVITRUM AB (SE) | 2005-12-21 | — | — | EP | disclosed |
| US-20040242554-A1 | CERTAIN ARYLALIPHATIC AND HETEROARYL-ALIPHATIC PIPERAZINYL PYRAZINES AND THEIR USE IN THE TREATMENT OF SEROTONIN-RELATED DISEASES | BIOVITRUM, AB, A STOCKHOLM, SWEDEN CORPORATION | 2004-12-02 | — | — | US | disclosed |
| US-20030092694-A1 | Certain arylaliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases | BIOVITRUM, AB, A STOCKHOLM, SWEDEN CORPORATION | 2003-05-15 | — | — | US | disclosed |
| US-6465467-B1 | DISEASES RELATED TO THE 5-HT2C RECEPTOR, ESPECIALLY EATING, MEMORY, MOOD, URINARY AND ANXIETY DISORDERS, SCHIZOPHRENIA, PAIN, SEXUAL DYSFUNCTIONS | BIOVITRUM AB (SE) | 2002-10-15 | — | — | US | disclosed |
| EP-1178973-A2 | NOVEL COMPOUNDS, THEIR USE AND PREPARATION | Pharmacia AB (SE) | 2002-02-13 | — | — | EP | disclosed |
| WO-2000076984-A2 | NOVEL COMPOUNDS, THEIR USE AND PREPARATION | BIOVITRUM AB (SE) | 2000-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092694-A1 | Certain arylaliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases | HTR2C, HTR3C, HTR2A | KCNA3 1321/4885PRKCA 4000/4885PRKCD 3447/4885 |
| US-20040242554-A1 | CERTAIN ARYLALIPHATIC AND HETEROARYL-ALIPHATIC PIPERAZINYL PYRAZINES AND THEIR USE IN THE TREATMENT OF SEROTONIN-RELATED DISEASES | HTR2C, HTR3C, HTR2A | KCNA3 1363/4885PRKCA 4038/4885PRKCD 3421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.